Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Power List / 2021 / Small Molecules / Nigel Langley

Nigel Langley

Global Technology Director at BASF

  • Profile

Meet Nigel Langley

Langley has written over 100 scientific publications and co-edited two books. He is also an adjunct professor at the University of Mississippi and a Fellow of the UK’s Royal Society of Chemistry. In 2018, he was awarded the Industry Research Achievement Award in Excipient Technology by the IPEC Foundation. He has been a member of the Executive Committee at IPEC Americas since 2010 and is currently Chair Elect. He is also helping to lead the Novel Excipients Initiative for IPEC Americas in collaboration with the IQ Pharma Consortium. “I have a passion and interest in innovation especially in the area of pharmaceutical excipients. I am hopeful that, in the coming years, excipient innovation will become a key driver in the pharmaceutical industry, in both biologics and small molecule drug development. Without the opportunity to develop new excipients that have been specifically designed to help address current and future formulation challenges – for example, in improving the stability of biologics and in the area of poorly soluble small molecules – these challenges will remain unmet and, as a consequence, optimal medicines will not be available to the patient.”

False

Advertisement

Recommended

False

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.